Financial Performance Summary - In 2025, the company achieved operating revenue of 525.57 million RMB, representing a year-on-year increase of 23.09% [2] - The net profit attributable to the parent company was 114.02 million RMB, showing a significant year-on-year growth of 122.01% [2] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 116.59 million RMB, with a year-on-year increase of 102.99% [2] - Total assets at the end of the reporting period reached 1,955.93 million RMB, up 11.35% year-on-year [2] - The equity attributable to the parent company was 1,492.15 million RMB, reflecting a year-on-year growth of 7.11% [2] Business Operations and Key Factors - The company's core business segment, DEL, maintained steady growth, contributing to overall profit enhancement due to high gross margins [3] - The UK subsidiary further solidified the development of the FBDD/SBDD platform, with milestone revenues achieved from client projects [3] - The OBT segment showed significant revenue growth through the commercialization of small nucleic acid projects, aided by the efficient operation of an automated high-throughput chemical synthesis platform [3] - The company reported a significant increase in operating profit of 125.67 million RMB, a year-on-year growth of 99.58% [5] - The total profit reached 125.91 million RMB, marking a year-on-year increase of 100.62% [5] Non-Operating Gains and Losses - The company experienced a decrease in fair value losses on financial liabilities, which positively impacted overall financial performance [4]

Group 1 - The company Chengdu XianDao expects a net profit attributable to shareholders of 104 million to 127 million yuan for the year 2025, representing an increase of 52.64 million to 75.64 million yuan compared to the previous year, which is a year-on-year increase of 102.5% to 147.29% [1] - The main reason for the performance change is the impact of the core business, with steady growth in the DEL business, which maintains a high gross margin, contributing to overall profit improvement [1] - The UK subsidiary has further consolidated the steady development of the FBDD/SBDD platform, with revenue from major business segments showing steady growth and milestone revenue achieved from DEL and FBDD/SBDD client projects [1] Group 2 - The new technology business segment is gradually showing commercial transformation, with the OBT segment expanding traditional nucleoside monomer synthesis while achieving significant year-on-year revenue growth through delivery molecule-related services [1] - The company’s self-designed and built automated high-throughput chemical synthesis platform is operating efficiently, driving year-on-year revenue growth in ChemSer [1] - The steady growth in main business revenue and simultaneous improvement in gross margin have led to an increase in profits for the reporting period [1]